Erasca, Inc. (ERAS) News
Follow Erasca, Inc. (ERAS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 26 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Erasca Q3'26 Results Scheduled for Nov. 11
Erasca is scheduled to report Q3'26 results on November 11; revenue is estimated at 0 USD and EPS at (0.13) USD. The report time is not specified.
EQUITY | Nov 04, 2026, 12:00 PM UTC
L
Erasca to present updated ERAS-0015 clinical data at EORTC-NCI-AACR symposium
Erasca said it will deliver an oral presentation on updated ERAS-0015 monotherapy clinical data, covering additional patients and longer follow-up from AURORAS-1 Phase 1. It also plans a poster on nonclinical combination
MACRO | Sep 10, 2026, 12:04 PM UTC
L
ERAS - Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERAS - Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
EQUITY | Sep 10, 2026, 12:02 PM UTC
L
Erasca to present at Morgan Stanley 24th Global Healthcare Conference
Erasca, Inc. announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 08, 2026, 11:08 AM UTC
L
ERAS - Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ERAS - Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
EQUITY | Sep 08, 2026, 11:00 AM UTC
M
Erasca wins FDA Fast Track for ERAS-0015 in pancreatic cancer
Erasca says the FDA granted Fast Track designation to its Pan-RAS molecular glue ERAS-0015 for patients with metastatic pancreatic adenocarcinoma.
REGULATION | Aug 24, 2026, 12:00 PM UTC
L
Erasca Q2 EPS $(0.14) Misses $(0.11) Estimate
Erasca (NASDAQ: ERAS ) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 16.67 percent decrease over losses of $(0.12) per share from the sa
EARNINGS | Aug 11, 2026, 08:39 PM UTC
L
ERAS - Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERAS - Erasca Reports Second Quarter 2026 Business Updates and Financial Results
EQUITY | Aug 11, 2026, 08:01 PM UTC
H
Erasca Sued for Securities Law Violations
Erasca faces securities law violations lawsuit
REGULATION | Jul 31, 2026, 06:58 AM UTC
L
ERAS PT raised from $21 to $24, maintains Buy @ JEFF
ERAS PT raised from $21 to $24, maintains Buy @ JEFF
EQUITY | Jul 15, 2026, 11:01 AM UTC
L
ERAS data update incrementally positive; registrational strategy taking shape @ GSCO
ERAS data update incrementally positive; registrational strategy taking shape @ GSCO
EQUITY | Jul 14, 2026, 01:00 PM UTC
L
Deal priced today • ERAS 31.4M share Spot Secondary, priced at $17.50, by JPMC, MSCO, JEFF & Evercore Deals to be priced today • QTTB $200M
Deal priced today • ERAS 31.4M share Spot Secondary, priced at $17.50, by JPMC, MSCO, JEFF & Evercore Deals to be priced today • QTTB $200M Secondary announced last night, shares & pricing TBD, by MSCO, JEFF, Cantor, OPC
REGULATION | Jul 14, 2026, 12:15 PM UTC
L
ERAS Erasca $500M Spot Secondary priced at $17.50; shares -1.5% premarket
ERAS Erasca $500M Spot Secondary priced at $17.50; shares -1.5% premarket
EQUITY | Jul 14, 2026, 10:47 AM UTC
H
Closing Bell Movers: Trex up 6% after positive Q2 pre-announcement
Fast-unraveling ceasefire between Iran and U.S. amid continued dispute over the control of transit through the Strait of Hormuz has reverberated across the asset classes in a predictable fashion on Monday. WTI Crude Oil
CENTRAL_BANK | Jul 13, 2026, 11:42 PM UTC
L
ERAS Erasca announces proposed public offering of $500M of common stock (more)
ERAS Erasca announces proposed public offering of $500M of common stock (more)
EQUITY | Jul 13, 2026, 08:19 PM UTC
L
ERAS -7.25% after study update, offering announced
ERAS -7.25% after study update, offering announced
EQUITY | Jul 13, 2026, 08:18 PM UTC
L
ERAS Erasca Inc: files for mixed shelf offering, size not disclosed - filing
ERAS Erasca Inc: files for mixed shelf offering, size not disclosed - filing
EQUITY | Jul 13, 2026, 08:16 PM UTC
L
ERAS Erasca - plans registration-enabling lung cancer trial in h1 2027; phase 3 pancreatic cancer trial in 2027
ERAS Erasca - plans registration-enabling lung cancer trial in h1 2027; phase 3 pancreatic cancer trial in 2027
EQUITY | Jul 13, 2026, 08:02 PM UTC
L
ERAS Erasca Inc: additional eras-0015 monotherapy and combination data expected h1 2027
ERAS Erasca Inc: additional eras-0015 monotherapy and combination data expected h1 2027
EQUITY | Jul 13, 2026, 08:02 PM UTC
L
ERAS Erasca announces updated preliminary phase 1 data and registration-enabling plans for potentially best-in-class pan-ras Molecular glue
ERAS Erasca announces updated preliminary phase 1 data and registration-enabling plans for potentially best-in-class pan-ras Molecular glue eras-0015 in kras-mutant solid tumors
EQUITY | Jul 13, 2026, 08:01 PM UTC
L
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders Have Opportunity to Lead Class Action Law
NEW YORK CITY, NY / / July 5, 2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-ri
EQUITY | Jul 05, 2026, 11:00 AM UTC
L
ERAS INVESTOR REMINDER: Erasca, Inc. Investors Have Until August 10, 2026 to Seek Lead Plaintiff Role
If you have suffered a loss on your
EQUITY | Jul 04, 2026, 12:00 AM UTC
L
Securities Fraud Class Action Filed Against Erasca, Inc. (ERAS) - Levi & Korsinsky Reminds Investors of August 10, 2026
NEW YORK, NY / / July 3, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise
EQUITY | Jul 03, 2026, 06:40 PM UTC
L
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS
SAN FRANCISCO, July 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ: ERAS) faces a sec
EQUITY | Jul 03, 2026, 06:19 PM UTC
L
Pomerantz LLP Calls Attention to Class Action Against Erasca, Inc. – ERAS
NEW YORK CITY, NY / / July 3, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against
EQUITY | Jul 03, 2026, 11:00 AM UTC
L
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Acti
NEW YORK CITY, NY / / July 2, 2026 / WHY: Rosen Law Firm, a global investor rights law firm, re
EQUITY | Jul 03, 2026, 01:45 AM UTC